Stockreport

Arbutus Announces Conclusion of LNP License Agreement with Alexion

Arbutus Biopharma Corporation  (ABUS) 
Last arbutus biopharma corporation earnings: 11/6 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.arbutusbio.com/node/5806
PDF Alexion Decision Driven by Strategic Review of R&D Activities Collaboration Enabled Further Optimization of LNP for Delivery of mRNAArbutus Views LNP as a Potential Sour [Read more]